virtual coin trading Top Block

During the year, there were 461 new indices, and the index investment fever continued to climb. On December 10th, in order to meet the investment demand of diversified indices, CSI Index Co., Ltd. officially released five new indices, including CSI 1000 Growth Index, CSI 1000 Value Index, CSI 2000 Growth Index, CSI 2000 Value Index and CSI 1000 Quality Balance Strategy Index. With the "listing" of the above five indexes, the number of newly-issued indexes reached 461 during the year, covering categories such as strategy, style, scale, industry, theme and other fixed-income indexes; Related index asset classes include stocks, fixed income, funds and futures. At the same time, the secondary market, this year, the heat of indexed investment is also high. Looking forward to the future, with the continuous vigorous growth of market demand and unabated heat, and the precise guidance and strong support from the supervisory level, the indexed investment ecology will become more and more perfect. (Securities Daily)Nikkei futures opened down 95 points at 39,290 on the Singapore Stock Exchange.Ministry of Finance of the Republic of Korea: We will pay close attention to the financial and foreign exchange market trends and take adequate measures to curb excessive fluctuations in the foreign exchange market.

Goldman Sachs: I don't agree that gold can't reach $3,000 under a strong dollar. Goldman Sachs said that we don't agree with the view that the price of gold can't rise to $3,000 per ounce by the end of 2025 when the dollar remains strong for a long time. We predict that gold will reach $3,000 per ounce by the end of 2025, and the reduction of interest rate cuts by the Federal Reserve (rather than the strengthening of the US dollar) is the downside risk of this prediction.Guotai Junan's annual strategy for innovative drugs in 2025: innovative pharmaceutical companies have accelerated into the harvest period, and the valuation has been at a historical low in the past five years. Guotai Junan said that the centralized purchasing policy has become stable, mature and normalized, and the marginal impact has weakened. Innovative drugs have gained policy inclination in the medical insurance negotiation. In the past two years, the policy has continued to promote pharmaceutical innovation, and the top-level design and local supporting chain support the development of innovative drugs. Commercial insurance is expected to bring new growth momentum to China's pharmaceutical market, and the overall industry trend is upward. At present, the trend of innovative drug industry is improving, the supply continues to accelerate, and a number of domestic innovative drugs are approved soon, which is expected to drive a new round of heavy volume. At the same time, the commercialization has achieved remarkable results and has occupied a dominant position in some sub-sectors. Pharma's performance continued to differentiate, and innovative drugs and just-needed drugs performed well. Biotech commercialization continues to increase, per capita yield continues to increase, the node of turning losses is approaching, and innovation ushers in the harvest period. Horizontal comparison: compared with overseas peers, the overall valuation of domestic innovative pharmaceutical companies is in a historically low range; Vertical comparison: the valuation of SW- pharmaceutical biology and SW- chemical preparations is at a historical low in the past five years, and it is expected that the valuation of subsequent sectors will pick up.Monetary policy has turned to "moderate easing", and experts say that it is expected to make greater efforts to lower the RRR and cut interest rates. The the Political Bureau of the Communist Party of China (CPC) Central Committee meeting held on December 9 changed the orientation of monetary policy from "steady" to "moderate easing" next year. Experts said that under the orientation of "moderate easing", the monetary policy space was further opened. In terms of total amount, it is more reasonable and sufficient to maintain liquidity; In terms of price, appropriately reducing the financing cost will better reflect the effectiveness of monetary policy. Next year, even greater RRR cuts and interest rate cuts can be expected. In addition to lowering the RRR and cutting interest rates, experts said that structural monetary policy tools, buying government bonds, open market buyout reverse repurchase and other operations are expected to continue to expand the scale, increase the frequency of use, and continuously enhance the effectiveness and pertinence of monetary policy. (CSI)

Asian Development Bank: Reduce India's growth forecast from 7.0% to 6.5% in 2024 and from 7.2% to 7.0% in 2025.ADB lowered the growth forecast of developing economies in the Asia-Pacific region to maintain China's economic growth forecast. On December 11th, the Asian Development Bank issued the Asia Development Outlook 2024 (December Edition). According to the report, the development momentum in the Asia-Pacific region is steady, but as US President-elect Trump is about to take office, changes in his trade, finance and immigration policies may inhibit the development of the Asia-Pacific region and aggravate inflation. ADB lowered its growth forecast for developing economies in the Asia-Pacific region from the previous 5.0% to 4.9% in 2024, and from the previous 4.9% to 4.8% in 2025. China's economic growth is expected to remain at 4.8% and 4.5% in 2024 and 2025 respectively, which is the same as before.The negotiation between Myriad and United Health Insurance may be extended to the beginning of 2025, and the negotiation between Myriad Genetics and UnitedHealthcare on the genetic test of Myriad may continue until the beginning of 2025. Myriad reiterated its estimate of the financial impact of the United Health Insurance Company's updated medical policy in 2024.